Boehringer Ingelheim (Japan)

Safety, tolerability and pharmacokinetics of an NMDA receptor subunit 2B-selective negative allosteric modulator, BI 1569912: Results of three partially randomised, placebo-controlled phase I trials

Background: BI 1569912 is an orally administered, GluN2B-selective negative allosteric modulator at the N-methyl-D-aspartate receptor. Aims: To investigate the safety, tolerability and pharmacokinetics (PK) of BI 1569912 in healthy males across three partially randomised, placebo...

Recent Advancesin Nonprecious Metal Catalysis

Abstract As part of a precompetitive alliance, Boehringer Ingelheim, Pfizer, and AbbVie publish a quarterly review series dedicated to recent advances in nonprecious metal catalysis (NPMC). By informing synthetic chemists about noteworthy developments in NPMC, these reviews aim t...